US Stem Cell Inc
U.S. Stem Cell, Inc. engages in the research, development, and commercialization of stem cell and regenerative treatments in the United States and internationally. The company develops MyoCell, an autologous muscle stem cell therapy which is preparing for phase II/III clinical trials for the treatment of heart damage in heart failure patients; MyoCell SDF-1, an autologous cell therapy which compl… Read more
US Stem Cell Inc (USRM) - Net Assets
Latest net assets as of March 2023: $-14.75 Million USD
Based on the latest financial reports, US Stem Cell Inc (USRM) has net assets worth $-14.75 Million USD as of March 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($68.04K) and total liabilities ($14.81 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-14.75 Million |
| % of Total Assets | -21671.98% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 93.95 |
US Stem Cell Inc - Net Assets Trend (2002–2022)
This chart illustrates how US Stem Cell Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for US Stem Cell Inc (2002–2022)
The table below shows the annual net assets of US Stem Cell Inc from 2002 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | $-14.75 Million | -15.50% |
| 2021-12-31 | $-12.77 Million | -10.25% |
| 2020-12-31 | $-11.58 Million | -22.15% |
| 2019-12-31 | $-9.48 Million | -37.74% |
| 2018-12-31 | $-6.88 Million | +3.07% |
| 2017-12-31 | $-7.10 Million | +11.45% |
| 2016-12-31 | $-8.02 Million | -3.85% |
| 2015-12-31 | $-7.72 Million | +29.12% |
| 2014-12-31 | $-10.89 Million | +20.75% |
| 2013-12-31 | $-13.75 Million | +5.81% |
| 2012-12-31 | $-14.60 Million | -21.52% |
| 2011-12-31 | $-12.01 Million | +0.05% |
| 2010-12-31 | $-12.02 Million | +10.41% |
| 2009-12-31 | $-13.41 Million | +5.79% |
| 2008-12-31 | $-14.24 Million | -158.60% |
| 2007-12-31 | $-5.50 Million | -227.71% |
| 2006-12-31 | $4.31 Million | -6.01% |
| 2005-12-31 | $4.59 Million | +346.98% |
| 2004-12-31 | $-1.86 Million | -235.20% |
| 2003-12-31 | $-554.00K | -170.30% |
| 2002-12-31 | $788.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to US Stem Cell Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11006828200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $634.40K | % |
| Other Components | $127.14 Million | % |
| Total Equity | $-14.75 Million | 100.00% |
US Stem Cell Inc Competitors by Market Cap
The table below lists competitors of US Stem Cell Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
XMax Inc.
NASDAQ:XWIN
|
$56.46K |
|
DAIWA COMPUTER
BE:M2V
|
$56.46K |
|
NATIONAL MICROFINANCE BANK PLC
DSE:NMB
|
$56.47K |
|
GEPA4F
SA:GEPA4F
|
$56.48K |
|
Aquarius Surgical Technologies Inc
PINK:AQQRF
|
$56.33K |
|
EDEL (EDL.SG)
STU:EDL
|
$56.33K |
|
YAMAHA CORP - Dusseldorf Stock Exchang
DU:YHA
|
$56.32K |
|
ALLOT COMMUN (AG6.SG)
STU:AG6
|
$56.27K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in US Stem Cell Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from -12,766,336 to -14,745,396, a change of -1,979,060.
- Net loss of 2,857,943 reduced equity.
- New share issuances of 85,000 increased equity.
- Other factors increased equity by 793,883.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-2.86 Million | -19.38% |
| Share Issuances | $85.00K | +0.58% |
| Other Changes | $793.88K | +5.38% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares US Stem Cell Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-12-31 | $131.18 | $0.00 | x |
| 2003-12-31 | $-68.81 | $0.00 | x |
| 2004-12-31 | $-201.89 | $0.00 | x |
| 2005-12-31 | $430.57 | $0.00 | x |
| 2006-12-31 | $358.77 | $0.00 | x |
| 2007-12-31 | $-416.73 | $0.00 | x |
| 2008-12-31 | $-975.54 | $0.00 | x |
| 2009-12-31 | $-760.04 | $0.00 | x |
| 2010-12-31 | $-442.31 | $0.00 | x |
| 2011-12-31 | $-210.38 | $0.00 | x |
| 2012-12-31 | $-99.65 | $0.00 | x |
| 2013-12-31 | $-54.59 | $0.00 | x |
| 2014-12-31 | $-22.29 | $0.00 | x |
| 2015-12-31 | $-8.47 | $0.00 | x |
| 2016-12-31 | $-0.33 | $0.00 | x |
| 2017-12-31 | $-0.02 | $0.00 | x |
| 2018-12-31 | $-0.02 | $0.00 | x |
| 2019-12-31 | $-0.02 | $0.00 | x |
| 2020-12-31 | $-0.03 | $0.00 | x |
| 2021-12-31 | $-0.03 | $0.00 | x |
| 2022-12-31 | $-0.02 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently US Stem Cell Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3483.21%
- • Asset Turnover: 1.21x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-78.11%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | -1174.87% | -462900.00% | 0.00x | 3.22x | $-9.34 Million |
| 2003 | 0.00% | -13126.09% | 0.05x | 0.00x | $-5.98 Million |
| 2004 | 0.00% | -6417.44% | 0.12x | 0.00x | $-5.33 Million |
| 2005 | -159.74% | -5413.05% | 0.02x | 1.28x | $-7.79 Million |
| 2006 | -305.77% | -12493.15% | 0.02x | 1.51x | $-13.61 Million |
| 2007 | 0.00% | -5775.76% | 0.03x | 0.00x | $-17.52 Million |
| 2008 | 0.00% | -24898.64% | 0.03x | 0.00x | $-12.78 Million |
| 2009 | 0.00% | -1068.44% | 0.19x | 0.00x | $-2.50 Million |
| 2010 | 0.00% | -11123.59% | 0.15x | 0.00x | $-3.96 Million |
| 2011 | 0.00% | -26878.61% | 0.07x | 0.00x | $-3.50 Million |
| 2012 | 0.00% | -6572.63% | 0.38x | 0.00x | $-2.56 Million |
| 2013 | 0.00% | -3271.33% | 1.12x | 0.00x | $-1.77 Million |
| 2014 | 0.00% | -109.62% | 10.04x | 0.00x | $-1.16 Million |
| 2015 | 0.00% | -74.93% | 9.56x | 0.00x | $-869.74K |
| 2016 | 0.00% | -67.15% | 7.21x | 0.00x | $-1.27 Million |
| 2017 | 0.00% | -63.06% | 3.45x | 0.00x | $-2.77 Million |
| 2018 | 0.00% | -32.24% | 3.69x | 0.00x | $-1.47 Million |
| 2019 | 0.00% | -124.84% | 34.20x | 0.00x | $-2.89 Million |
| 2020 | 0.00% | -1043.17% | 3.14x | 0.00x | $-1.73 Million |
| 2021 | 0.00% | -1637.58% | 3.94x | 0.00x | $-2.01 Million |
| 2022 | 0.00% | -3483.21% | 1.21x | 0.00x | $-1.38 Million |
Industry Comparison
This section compares US Stem Cell Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,595,389
- Average return on equity (ROE) among peers: -116.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| US Stem Cell Inc (USRM) | $-14.75 Million | -1174.87% | N/A | $56.37K |
| Aadi Bioscience Inc (AADI) | $17.44 Million | -122.74% | 0.21x | $17.03 Million |
| America Great Health (AAGH) | $-5.31 Million | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $274.16 Million | -147.88% | 8.55x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $54.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $4.67 Million | -803.57% | 14.26x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $731.78 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $193.84 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $102.67 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $345.85 Million |